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Abstract
Dysregulation of the mammalian target of rapamycin (mTOR) signaling has been found in many human cancers, particularly
those with loss of the tumor suppressor PTEN. However, mTORC1 inhibitors such as temsirolimus have only modest activity
when used alone and may induce acquired resistance by activating upstream mTORC2 and Akt. Other tumors that do not
depend upon PI3K/Akt/mTOR signaling for survival are primarily resistant. This study tested the hypothesis that the limited
clinical efficacy of temsirolimus is due to a compensatory increase in survival signaling pathways downstream of Akt as well
as an incomplete block of 4E-BP1-controlled proliferative processes downstream of mTOR. We explored the addition of a
PI3K inhibitor to temsirolimus and identified the mechanism of combinatorial synergy. Proliferation assays revealed that
BEZ235 (dual PI3K/mTOR inhibitor) or ZSTK474 (pan PI3K inhibitor) combined with temsirolimus synergistically inhibited cell
growth compared to cells treated with any of the agents alone. Co-treatment resulted in G0/G1 cell cycle arrest and up-
regulation of p27. Cell death occurred through massive autophagy and subsequent apoptosis. While molecular profiling
revealed that, in most cases, sensitivity to temsirolimus alone was most marked in cells with high basal phospho-Akt
resulting from PTEN inactivation, combining a PI3K inhibitor with temsirolimus prevented compensatory Akt
phosphorylation and synergistically enhanced cell death regardless of PTEN status. Another molecular correlate of synergy
was the finding that temsirolimus treatment alone blocks downstream S6 kinase signaling, but not 4E-BP1. Adding BEZ235
completely abrogated 4E-BP1 phosphorylation. We conclude that the addition of a PI3K inhibitor overcomes cellular
resistance to mTORC1 inhibitors regardless of PTEN status, and thus substantially expands the molecular phenotype of
tumors likely to respond.
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Introduction
Alterations in the phosphoinositide-3-kinase (PI3K)/Akt/mam-
malian target of rapamycin (mTOR) signaling pathway have been
found in many human tumors. In particular, amplification and
mutation of PIK3CA, mutation of PIK3R and Akt, and loss of
tumor suppressor PTEN (phosphatase and tensin homolog deleted
from chromosome 10) contribute to constitutive activation of this
signaling pathway [1,2,3,4]. Understanding the interplay among
signaling molecules in the PI3K/Akt/mTOR pathway is of utmost
importance. Two distinct mTOR complexes, mTORC1 and
mTORC2, have been identified and have differential sensitivity to
rapamycin. mTORC1 is downstream of Akt, sensitive to
rapamycin inhibition, and controls cap-dependent protein trans-
lation [5]. The two best-studied mTORC1 substrates are 40S
ribosomal S6 kinase 1 (S6K1) and eukaryotic translation initiation
factor 4E-binding protein 1 (4E-BP1), which mediate efficient
protein translation. In contrast, mTORC2 is directly upstream of
Akt and is resistant to rapamycin. Akt can be activated by
phosphorylation at two different sites, S473 by mTORC2 and
T308 by phosphoinositide-dependent kinase 1 (PDK1). Constitu-
tive activation of the PI3K/Akt/mTOR signaling axis leads to
uncontrolled tumor cell proliferation and survival [1].
Given the importance of the mTOR pathway in cancer cell
growth, significant efforts have attempted to identify targeted
inhibitors. Rapamycin and its analogs (rapalogs), such as RAD001
(everolimus), AP23573 (ridaforolimus) and CCI-779 (temsirolimus)
are allosteric inhibitors of mTOR [6]. However, single agent
rapalogs have only achieved modest antitumor activity in the clinic
[7]. The limited anticancer efficacy of the rapalogs can be
explained by two possible mechanisms: (1) rapalogs inhibit only
mTORC1 (not mTORC2), thereby inducing feedback activation
of survival signaling pathways such as Akt phosphorylation [7,8,9];
or (2) rapalogs incompletely block mTORC1 downstream
signaling. For example, in some cells mTOR inhibitors prevent
phosphorylation of S6K1 but not 4E-BP1, thus allowing the cells
to escape growth inhibition [10,11,12].
Previous studies indicate that PTEN inactivation, PIK3CA
mutation, and mTOR dysregulation are common molecular
signatures for endometrial carcinoma [1,13]. Furthermore, PI3K
activation is a hallmark for aggressive tumors at this site [14].
mTOR inhibitors (temsirolimus, everolimus, and ridaforolimus)
have been tested in phase I and II clinical trials for advanced and
recurrent endometrial carcinomas with some promising clinical
outcomes; however, response rates are not robust. In general,
responses are partial and vary from 8%–26% with an additional
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months [15]. Some patients achieve no benefit from therapy
(primary resistance), whereas in others, stable disease or an initial
response occurs. Nevertheless, most patients eventually experience
progression of disease (acquired resistance). More information will
be available following the analysis of the phase II trial of
temsirolimus for advanced endometrial cancer, Gynecologic
Oncology Group trial 248; however, since this trial only recently
closed to accrual, the outcome data are not mature.
In this current study, we investigated how inhibition of mTOR
can be optimized. We examined the growth inhibitory effect of
temsirolimus on a panel of endometrial cancer cells and observed
differential sensitivity as well as compensatory Akt phosphorylation
in a subset of cell lines, which may represent one mechanism for
acquired resistance. We identified cells which were primarily
resistant to treatment and compared these to other cells which
initially responded but employed escape mechanisms to achieve
acquired resistance. To overcome both forms of resistance, we
applied dual inhibition of PI3K and mTOR to prevent cell
survival signaling. Our data reveal that combination treatment of
temsirolimus with either BEZ235, a dual PI3K/mTOR inhibitor,
or ZSTK474, a pan PI3K inhibitor, blocked Akt activation and
inhibited phosphorylation of both 4E-BP1 and the substrate for
S6K, ribosomal S6 (rS6), which ultimately resulted in synergistic
cell death.
Materials and Methods
Cell lines
Six endometrial cancer cell lines (AN3CA, RL95-2, Hec1A,
SKUT1B, ECC-1, and KLE) were obtained from ATCC and
grown according to the recommended guidelines. Two endome-
trial cancer cell lines, Ishikawa H and Hec50co (gifts from Dr.
Erlio Gurpide, New York University), were grown in DMEM
supplemented with 10% fetal bovine serum (FBS) and penicillin-
streptomycin, all from Gibco.
Reagents
Temsirolimus, NVP-BEZ235, and ZSTK474 were purchased
from LC Laboratory and resuspended in DMSO. Antibodies
against Akt (#4691), Akt P-S473 (#4060), Akt P-T308 (#2965),
rS6 (#2217), rS6 P-S235/S236 (#4858), p70S6K (#9202),
p70S6K P-T389 (#9205), p27 (#3686), LC3 (#2775), 4E-BP1
(#9644), 4E-BP1 P-T37/T46 (#2855), and PARP (#9542) were
from Cell Signaling. The PTEN (sc-7974) antibody was from
Santa Cruz Biotechnology. The b-actin antibody (#A1978) was
from Sigma Aldrich.
Cell viability assays
Ninety-six-well plates were seeded with 10,000–20,000 cells in
each well 24 hrs prior to drug treatment. Cells were treated with
inhibitors or DMSO control for 3 days. Each experiment was
carried out in triplicate. Effects on cell proliferation and loss of cell
viability were evaluated with WST-1 (Clontech) assay per
manufacturer’s instructions.
Western blotting
Equal numbers of cells were plated 24 hrs prior to treatment.
Unless otherwise noted, cells were grown in the presence of
inhibitors for 24 hrs. Cells were solubilized in cold NP-40 cell lysis
buffer (150 mM NaCl, 50 mM Tris/HCl, pH 7.4, 1% NP-40, and
a protease and phosphatase inhibitor cocktail from Pierce). Lysates
were analyzed by Western blotting with specific primary and
HRP-conjugated secondary antibodies.
Cell cycle analysis
Cells were grown for 24 hrs in normal growth media followed
by drug treatment for an additional 24 or 72 hrs. Floating cells
were collected with the media, and attached cells were collected by
trypsinization. After centrifugation, the cell pellets were fixed in
70% cold ethanol, treated with RNAase A, stained with propidium
iodide, and prepared for flow cytometry. FACScan (BD
Bioscience) was used to detect the samples and ModFit was used
to analyze the cell cycle alterations.
Results
Cells display varying responses to temsirolimus
To establish a cell-based model system to understand the
efficacy of mTOR inhibitors in endometrial cancer patients, we
tested the growth-inhibitory properties of temsirolimus on eight
endometrial cancer cell lines using in vitro proliferation assays.
Proliferation of four endometrial cancer cell lines (SKUT1B,
AN3CA, RL95-2, and ECC-1) was inhibited at low nanomolar
concentrations of temsirolimus (Fig. 1A). The temsirolimus IC50
for these sensitive cells was approximately 1 nM (Supporting
Table S1), indicating a strong growth inhibitory impact. In
contrast, Ishikawa H, Hec50co, Hec1A and KLE cells were more
resistant to treatment, and the average IC50, when reached, was at
least 10-fold higher (Fig. 1B, Supporting Table S1).
To understand the signaling pathways responsible for the
contrasting effects of temsirolimus on proliferation, we first
confirmed functional inhibition of mTOR activity. Surprisingly,
even in the sensitive cell lines, phosphorylation of mTOR at S2448
was only partially inhibited by temsirolimus (Supporting Fig. S1),
suggesting that loss of mTOR phosphorylation does not distinguish
between sensitive and resistant cells. However, temsirolimus
completely prevented phosphorylation of rS6, which is downstream
of mTORC1, in all the cells regardless of sensitivity and at all tested
concentrations (Fig. 1C, D). This finding validates the functional
inhibition of mTORC1 activity despite the persistence of some
phosphorylation, although reduced, at the S2448 site (Fig. 1C, D
and Supporting Fig. S1). We conclude that mTOR inhibition at
S2448 and loss of rS6 activation as readouts do not adequately
distinguish between cells that are sensitive initially versus those that
are primarily resistant to temsirolimus-induced growth inhibition.
Akt phosphorylation status distinguishes between
sensitive and resistant cells
To understand the basis for cell sensitivity to temsirolimus as a
single agent, we turned to an analysis of Akt activation, both at
baseline and in response to treatment. We found that the baseline
constitutive activation of Akt was predictive of cell sensitivity with
the most resistant cells having very low basal S473 and T308
phosphorylation (Fig. 1C, D). After treatment with temsirolimus, a
compensatory increase in Akt phosphorylation at both sites was
detected in the most sensitive endometrial cancer cell lines tested
(Fig. 1C), but the primarily resistant cells (KLE) demonstrated no
Akt phosphorylation at either site, and another resistant line,
Hec50co, showed reduced phosphorylation (Fig. 1D). Thus, in
contrast to sensitive cells, primarily resistant cells have low basal
Akt phosphorylation and do not respond with compensatory
hyper-phosphorylation after temsirolimus treatment. Of note,
phospho-PDK1, the kinase responsible for Akt phosphorylation at
T308, is low in several resistant cell lines such as Hec1A and KLE
(Fig. 2). This indicates primary cell resistance and a general lack of
dependence on the Akt signaling pathway for proliferation. On the
other hand, the finding of compensatory activation of Akt in
responsive cells is consistent with previous reports in the literature
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human xenograft models, and patient tumors [16]. Compensatory
hyper-Akt phosphorylation suggests one potential mechanism
whereby cells that are initially sensitive escape the growth
inhibitory effects of the drug and become secondarily resistant.
From these data, we distinguish between primary resistance with a
lack of baseline Akt dependence versus acquired resistance
demonstrated by hyper-Akt activation in response to temsirolimus.
Figure 1. Temsirolimus differentially regulates cell viability and Akt phosphorylation in a dose-dependent manner. A, B, Endometrial
cancer cells were treated with increasing doses of temsirolimus for 72 hrs. Results are separated by (A) sensitivity or (B) resistance as determined by
cell viability. C, D, Phosphorylation of rS6 (P-rS6) and Akt (P-Akt T308 and P-Akt S473) after treatment with indicated doses of temsirolimus for 72 hrs
in temsirolimus-sensitive (C) or temsirolimus-resistant (D) cells was determined by Western blotting. Expression of total rS6 and Akt protein serves as
loading controls.
doi:10.1371/journal.pone.0026343.g001
mTOR and PI3 Kinase Inhibitor Synergy
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26343Baseline expression of PTEN as a correlate with Akt
activation and primary sensitivity
Endometrial cancer is frequently accompanied by the loss of
functional PTEN: 30%–83% have PTEN mutations or loss of PTEN
expression [17,18,19]. Loss of the PTEN tumor suppressor has been
proposed to correlate with mTOR inhibitor sensitivity in some other
cancer cell lines and patient tumors [20,21]. As discussed above,
Figures 1 and 2 demonstrate the presence of basal phospho-Akt in
some of the endometrial cancer cell lines, which we propose is a
marker for initial sensitivity to single agent temsirolimus, with
compensatory hyper-phosphorylation as a marker for developing
acquired resistance. To understand the basis for high baseline Akt
phosphorylation, we compared the baseline expression of PTEN and
phospho-Akt in eight endometrial cancer cell lines. As shown in
Figure 2, five cell lines (RL95-2, AN3CA, SKUT1B, ECC-1, and
Ishikawa H) showed PTEN loss, and three cell lines (Hec50co,
Hec1A,andKLE)expressedPTEN.Formostcelllines,theexception
being Hec50co, an inverse relationship was found between Akt
phosphorylation at S473 and PTEN loss such that the cells with
absent PTEN exhibited higher Akt S473 phosphorylation levels
(Fig. 2). Strikingly, the cells with the lowest level of PTEN expression
were also the most sensitive and responded with decreased cell
proliferation when treated with temsirolimus (Fig. 1A). Conversely,
the three cell lines with PTEN expression showed lower Akt S473
phosphorylation and were relatively resistant to mTOR inhibition. It
should be noted that Ishikawa H cells have high Akt phosphorylation
and loss of PTEN but are relatively resistant to temsirolimus.
Hec50co cells, which have high Akt phosphorylation and maintain
PTEN expression, are also resistant to temsirolimus. These data
confirm the general, but not absolute, correlation between PTEN loss
and constitutive Akt baseline activation at S473 as a marker for
primary cell sensitivity in the most responsive cells.
Dual therapy: PI3K inhibitors reverse temsirolimus-
induced Akt phosphorylation
To overcome the compensatory Akt phosphorylation induced
by temsirolimus treatment as a mechanism of acquired cell
resistance, six candidate inhibitors were chosen based on
previously reported efficacy (Supporting Table S2). Ishikawa H
(type I endometrial cancer cells) and Hec50co cells (type II
endometrial cancer cells) [22] were first used to test the efficacy of
these agents alone and in combination with temsirolimus. As
shown in Figure 3A, Ishikawa H and Hec50co cells displayed a
basal level of Akt phosphorylation that was further increased by
temsirolimus treatment, with Ishikawa H cells showing higher
levels compared with Hec50co cells, as discussed above (also,
Fig. 1C, D). BEZ235 (dual mTOR/PI3K inhibitor) and ZSTK474
(PI3K inhibitor) decreased the basal level of Akt phosphorylation
in both cell lines tested when used alone (Fig. 3A). Strikingly, when
combined with temsirolimus, both BEZ235 and ZSTK474
blocked the temsirolimus-induced hyper-phosphorylation of Akt.
We tested four other endometrial cancer cell lines and observed a
similar pattern of inhibition of Akt phosphorylation (Fig. 3B, left
panel). In order to demonstrate the effect of drug treatment even
on resistant KLE and Hec1A cells, which have very low levels of
basal phospho-Akt, we exposed the immunoblot for extended
periods of time (Fig. 3B). The effect of the treatment regimens was
preserved in these cells as well even though the baseline levels of
phospho-Akt were substantially reduced. A marker for temsir-
olimus activity is the loss of phosphorylation of p70S6K, which is
directly downstream of mTORC1. Accordingly, we detected a loss
of phospho-S6K whereas total S6K levels were generally
unchanged (Fig. 3B, right panel). This result confirms that
whether temsirolimus is used alone or in combination, this cellular
response is maintained.
In contrast to BEZ235 and ZSTK474, other molecular
inhibitors including AZD6244 (MEK inhibitor), LBH589 (HDAC
inhibitor), LY29004 (PI3K inhibitor), or AZD2171 (VEGFR/
PDGFR inhibitor) did not reverse temsirolimus-mediated com-
pensatory Akt phosphorylation in Hec50co and Ishikawa H cells
(Fig. 3A and Supporting Fig. S2), though these inhibitors have
been previously shown to block rapalog-induced Akt phosphory-
lation in other cell lines [23,24,25]. Based upon these data, we thus
narrowed our focus to the study of BEZ235 and ZSTK474, which
Figure 2. Baseline expression of PTEN, phospho-Akt and phospho-PDK1. Eight endometrial cancer cell lines were grown without treatment.
Total protein extracts were analyzed by Western blotting for PTEN, phospho-Akt (P-Akt S473 and P-Akt T308), total Akt, phospho-PDK1 (P-PDK1 S241),
and total PDK1. b-actin expression served as a loading control.
doi:10.1371/journal.pone.0026343.g002
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inhibition.
Combination treatment synergistically inhibits cell
growth in endometrial cancer cell lines
After demonstrating BEZ235 and ZSTK474’s effectiveness in
down-regulating temsirolimus-induced Akt hyper-phosphoryla-
tion, we examined the anti-proliferative properties of combined
treatment of temsirolimus with BEZ235 or ZSTK474. A broad
range of doses — either BEZ235 or ZSTK474 alone or in
combination with temsirolimus— were tested in order to
determine the optimal concentration for eliciting growth inhibitory
effects. First, the panel of endometrial cancer cells were treated
with single drug (BEZ235 or ZSTK474 at 1–1000 nM) and
compared to vehicle (DMSO) control. BEZ235 alone reduced cell
proliferation by 50% at doses as low as 1–50 nM (Fig. 4A).
ZSTK474 alone was cytostatic in all the eight tested endometrial
cancer cell lines; it inhibited cell growth at about 100–1000 nM
(Fig. 4B).
However, when either BEZ235 or ZSTK474 was combined
with low dose temsirolimus (1 nM), cell proliferation was inhibited
in a synergistic manner compared to BEZ235 or ZSTK474 alone.
Notably, a 50% reduction in proliferation occurred with combined
temsirolimus and BEZ235 at a lower concentration of BEZ235
Figure 3. Temsirolimus-induced Akt phosphorylation is decreased by BEZ235 and ZSTK474, but not by AZD6244. A, Ishikawa H
(upper panels) and Hec50co (lower panels) cells were grown for 24 hrs and treated overnight with the indicated inhibitors. Phospho-Akt (P-Akt S473)
and total Akt were assessed by Western blotting. B, Endometrial cancer cell lines were treated with the indicated inhibitors overnight. Total protein
extracts were analyzed by Western blotting for P-Akt S473 and total Akt (left panels) or phospho-p70S6K T389 (P-S6K) and total p70S6K (S6K, right
panels). Phospho-Akt blots for Hec1A and KLE cells were subjected to a long exposure to visualize low levels of Akt phosphorylation.
doi:10.1371/journal.pone.0026343.g003
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with 1 nM temsirolimus resulted in a dose-dependent synergistic
effect on cell proliferation at concentrations similar to BEZ235
with temsirolimus (Fig. 4B). The synergistic effect was seen in all
cell lines except KLE, in which the drug combinations exhibited
an additive effect. Combination indices were calculated and are
shown in Supporting Table S1. These data signify that inhibiting
both the upstream and downstream components of PI3K/Akt/
mTOR signaling is an effective approach to synergistically
decrease cell proliferation.
Co-treatment of BEZ235 or ZSTK474 with temsirolimus
induces G1 cell cycle arrest and up-regulates p27
Temsirolimus and BEZ235 have been reported to inhibit cancer
cell growth by inducing G0/G1 cell cycle arrest [26,27]. Since we
have two cell populations whose proliferation is differentially
affected by temsirolimus treatment (sensitive vs. resistant), we
chose two representative cell lines (AN3CA-sensitive; Hec50co-
resistant) as models to test the combination approach on cell cycle
progression. Cell cycle content analysis of AN3CA cells demon-
strated that temsirolimus treatment increased the percent of cells
Figure 4. Combination treatment of BEZ235 or ZSTK474 with temsirolimus synergistically inhibits cell proliferation. A, B, Cell viability
was determined in the indicated endometrial cancer cell lines after treatment with increasing concentrations of (A) BEZ235 or (B) ZSTK474 alone or in
the presence of 1 nM temsirolimus for 72 hrs.
doi:10.1371/journal.pone.0026343.g004
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(Fig. 5A). Co-treatment with BEZ235 and temsirolimus led to a
slight increase of cells in G1 compared to temsirolimus alone at
24 hours (Fig. 5A). In contrast, treatment of Hec50co cells with
temsirolimus alone caused a 4% increase in the G1 population,
which required 72 hours of prolonged exposure to demonstrate
(Fig. 5B). However, when temsirolimus was combined with
BEZ235, the G1 population increased to 60% by 72 hours
(Fig. 5B). Further, ZSTK474 effects in combination with
temsirolimus (Fig. 5C) replicated those of BEZ235 (Fig. 5A),
suggesting that G1 arrest is a common method by which combined
inhibition of PI3K and mTOR achieves the decrease in cell
viability observed in Figure 4. Also of note, the G1 block was
achieved rapidly in sensitive cells, but eventually was observed
even in resistant cells.
Expression of the cyclin dependent kinase inhibitor, p27, was
next tested in order to explore the cell cycle regulatory proteins
downstream of mTOR that might explain the G1 block. As shown
in Figure 5D, single and combined drug treatments promoted
increased expression of p27 at the protein level, implicating
induction of p27 in the mechanism of G1 arrest.
Combined treatment induces autophagy as a mechanism
of cell death
We next characterized the mechanism of cell death in response
to combination therapy. Examination of several apoptotic
markers, including caspase 3, revealed that the cells did not
undergo caspase-dependent apoptosis (data not shown). However,
several studies have demonstrated that both down-regulation of
Akt [28,29] and treatment with rapalogs [26] promote autophagy,
which can lead to caspase-independent apoptosis characterized by
poly (ADP-ribose) polymerase (PARP) cleavage [30,31]. There-
fore, we first tested processing of microtubule-associated protein
light chain 3-I (LC3-I), which is a common marker for autophagy
[32]. As noted in Figure 6A, under our experimental conditions,
no loss of LC3-I occurred upon temsirolimus treatment when
compared with control. In contrast, BEZ235 alone dramatically
reduced the level of LC3-I in all tested cells. Furthermore,
combination of temsirolimus with ZSTK474 reduced levels of
LC3-I compared with ZSTK474 alone. The reduction in LC3-I
levels was accompanied by the expected increase or maintenance
of LC3-II in some cell lines (Ishikawa H and Hec50co), further
confirming that the cells are undergoing autophagy (Fig. 6A).
Since others have reported that BEZ235 induces caspase-
independent apoptosis through PARP cleavage [30], we treated
cells for longer periods of time (48 to 72 hrs) and examined PARP
cleavage as a marker of apoptotic cell death. In both sensitive and
resistant cell lines, we observed PARP cleavage following
treatment with BEZ235 or ZSTK474, and addition of temsir-
olimus did not substantially increase the effect (Fig. 6B).
Collectively, these data suggest that the mechanism of cell death
involves massive autophagy which proceeds into caspase-indepen-
dent apoptosis.
Mechanism of synergy between PI3K and mTOR
inhibitors
Recently, several groups reported that 4E-BP1, not rS6, which
are both downstream of mTORC1, is critical for controlling
oncogenic Akt signaling [10,11]. Additionally, it was demonstrated
the BEZ235 is more effective at down-regulating 4E-BP1
phosphorylation as compared to rapamycin and second-genera-
tion mTOR inhibitors [11]. ZSTK474 targets PI3K, which is
upstream of PI3K/Akt/mTOR signaling, while temsirolimus
inhibits mTORC1, which is downstream of this pathway. This
strategy, targeting both ends of the same pathway, clearly
demonstrated synergy in cell proliferation assays (Fig. 4B).
However, BEZ235 itself is a dual PI3K/mTOR inhibitor that
functions both upstream and downstream of the PI3K/Akt/
mTOR pathway and should be sufficient to completely block
signaling; nevertheless, a synergistic effect was observed when
BEZ235 was combined with another mTOR inhibitor, temsir-
olimus. This finding was unexpected, and we sought an
explanation for why blocking mTORC1 with two different agents
produced synergy. We addressed this question by examining the
individual effect of BEZ235 and temsirolimus on downstream
components of mTORC1 pathway signaling (Fig. 7A, B). The
downstream components tested were 4E-BP1 and rS6 (Fig. 7C).
Surprisingly, temsirolimus had little or no effect on inhibiting 4E-
BP1 phosphorylation compared with control despite its ability to
fully block phosphorylation of rS6 (Fig. 7B). On the other hand,
BEZ235 completely blocked 4E-BP1 phosphorylation in all tested
cell lines but had less effect on rS6 phosphorylation (Fig. 7A, B).
When testing the phosphorylation of rS6, we discovered that
temsirolimus inhibited it much more effectively (at 1 nM) than
BEZ235 at the same concentration (Fig. 7B and Supporting Fig.
S3). In summary, to fully block both of the important downstream
effectors, both drugs were required. Figure 7C is a schematic
model to summarize our findings on the specific mechanistic
functions of PI3K/Akt/mTOR inhibitors in the treatment of
cancers that are reliant on this pathway.
Discussion
Temsirolimus is currently in phase II trials for advanced
endometrial cancer and has shown some promise. However, lack
of initial response to therapy as well as the development of
acquired drug resistance continues to be problematic. To more
fully understand the therapeutic potential of mTOR inhibition in
endometrial cancer, we first examined the effect of temsirolimus
alone on the viability of a panel of endometrial cancer cell lines.
We sought to distinguish between cellular events which predict for
primary resistance as well as those events which are linked to the
eventual development of acquired resistance. Consistent with
other types of cancer, primary resistance to temsirolimus is found
in a subset of these cell lines. Our data suggest that primarily
resistant cells lack robust Akt signaling, are unable to phosphor-
ylate Akt at baseline, and express PTEN. In contrast, the most
sensitive cell lines have lost PTEN expression and have high
baseline phosphorylation of Akt. Our data demonstrate that in
these cells, temsirolimus treatment promotes a further increase in
Akt phosphorylation, indicating that signaling through the pro-
survival PI3K/Akt pathway is likely how these endometrial cancer
cell lines eventually circumvent mTOR inhibition. These results
are consistent with previous reports in other types of cancers
documenting compensatory Akt phosphorylation in response to
other rapalogs [7,16,24]. This has been observed in xenograft
models of lung cancer [24] as well as in advanced colon and breast
cancer tissues following rapalog therapy [16]. The elevated Akt
phosphorylation is thought to be a predominant driving force in
resistance to temsirolimus treatment in these cancers [7].
To overcome resistance, we adopted a combination strategy.
Dual treatment with temsirolimus and the PI3K inhibitor
ZSTK474 or the PI3K/mTOR inhibitor BEZ235 overcame the
temsirolimus-induced Akt hyper-phosphorylation, which is a
marker for developing acquired resistance; furthermore, this
treatment strategy synergistically decreased viability and promoted
G1 cell cycle arrest even in the cell lines that were primarily
mTOR and PI3 Kinase Inhibitor Synergy
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Hec50co (B) cells were treated for 24 hrs or 72 hrs, respectively, with vehicle (DMSO) or BEZ235 (1 nM–100 nM) in the presence or absence of 1 nM
temsirolimus. Cell cycle distribution was analyzed by flow cytometry and the percentage of cells in G1 determined. C, AN3CA cells were treated for
24 hrs with vehicle (DMSO) or ZSTK474 (1 mM) in the presence or absence of 1 nM temsirolimus. Cells were analyzed as in A. D, Expression of the
cyclin-dependent kinase inhibitor p27 was assessed by Western blotting 24 hrs after the indicated treatments.
doi:10.1371/journal.pone.0026343.g005
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a recent study in melanoma cells in which dual treatment with the
PI3K inhibitor PI-103 and rapamycin reversed compensatory Akt
phosphorylation and induced cell cycle arrest, and xenograft
studies demonstrated reduced tumor growth with this combination
strategy [33]. We extend these findings herein to define a potential
mechanism by which the combination therapy promotes cell
death.
Figure 6. Combination treatment induces autophagy and PARP cleavage. (A) Expression of the autophagy marker LC3 was assessed by
Western blotting after the indicated treatments for 24 hrs. Arrows denote full-length LC3-I (16 kDa) and cleaved LC3-II (14 kDa). (B) PARP cleavage
was assessed by Western blotting after the indicated treatments for 48 hrs–72 hrs. Arrows denote full-length PARP (116 kDa) and cleaved PARP
(89 kDa).
doi:10.1371/journal.pone.0026343.g006
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mTORC2 activity, in particular 4E-BP1 phosphorylation at a dose
of 100 nM. However, BEZ235 was less effective in blocking rS6
phosphorylation. In comparison, temsirolimus completely abro-
gated phosphorylation of rS6 at 1 nM. Thus, combining both
agents (BEZ235 and temsirolimus) completely inhibited signaling
throughout the pathway and synergistically induced cell death.
Currently, combinatorial therapies are being applied to prevent
resistance to single-agent treatments such as rapalogs. Examples of
targeted small-molecule inhibitors under investigation include
BEZ235 (dual PI3K/mTOR inhibitor) [27], AZD2171 (dual
VEGF2/PDGFR inhibitor); LBH589 (histone deacetylase inhib-
itor) [23], LY294002 (PI3K inhibitor) [24], AZD6244 (MEK
inhibitor) [25], and ZSTK474 (PI3K inhibitor) [34]. BEZ235 is a
novel orally bioavailable inhibitor originally designed as a pan-
PI3K family inhibitor based on the p110c (catalytic subunit of
PI3K) kinase domain structure [6,27]. Interestingly, when this
compound was evaluated in preclinical studies, in vitro kinase assays
revealed it also targets mTOR at a concentration of 20.7 nM [27].
Therefore, BEZ235 is classified as a dual inhibitor that is capable
Figure 7. Mechanism of synergistic effect for combination treatment of temsirolimus and BEZ235. A, Phosphorylation of 4E-BP1 (P-4E-
BP1 T37/T46) was assessed after incubating cells with the indicated treatments for 24 hrs. Total 4E-BP1 expression serves as a loading control. B, Cells
were treated with 1 nM or 10 nM temsirolimus or BEZ235 for 72 hrs then phosphorylation of rS6 (P-rS6 S235/S236) determined by Western blotting.
Total rS6 serves as a loading control. C, Proposed mechanism for synergistic effect. Temsirolimus blocks one arm of mTORC1 signaling as evidenced
by lack of phosphorylation of rS6. As a dual inhibitor of PI3K and mTOR, BEZ235 acts both upstream as well as downstream of mTORC1 and mTORC2
through inhibition of Akt (upstream) and 4E-BP1 (downstream) phosphorylation. BEZ235 has minimal effects on rS6 phosphorylation, but
combination with temsirolimus blocks both arms of mTORC1 signaling. As a specific PI3K inhibitor, ZSTK474 acts upstream of the PI3K/Akt/mTOR
signaling pathway, and in combination with temsirolimus, can block rS6 but not 4E-BP1 activation.
doi:10.1371/journal.pone.0026343.g007
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mTORC2) of the PI3K/Akt/mTOR axis. BEZ235 has been
reported to inhibit growth and proliferation and induce apoptosis
in a variety of tumor cell lines [27,35], including breast cancer cells
with mutant or amplified PIK3CA [30]. BEZ235 showed antitumor
activity in nude mice with few side effects [27]. A recent report
from a phase I study of BEZ235 in 59 patients with advanced solid
tumors demonstrated antitumor effects and a favorable safety
profile [36]. ZSTK474, a pan-class I PI3K inhibitor, also
demonstrated high potency against a panel of cancer cell lines
and human tumor xenografts without toxicity to major organs
[34,37]. As discussed above, among all drugs tested, the agents
which produced synergy with temsirolimus in our models were
BEZ235 and ZSTK474.
A main conclusion of our study is that combination treatment of
ZSTK474 or BEZ235 with temsirolimus synergizes to decrease
viability in endometrial cancer cell lines. A potential mechanism of
synergy from co-treatment with ZSTK474 and temsirolimus is the
vertical blockade of hyper-activated PI3K/Akt/mTOR signaling,
specifically the simultaneous targeting of the upstream component
PI3K by ZSTK474 and the downstream component mTOR
(p70S6K) by temsirolimus. Temsirolimus alone only blocks rS6K
activity downstream of mTORC1, whereas signaling through the
other mTORC1 target 4E-BP1 is left intact. It has been
documented in the literature that signaling through 4E-BP1 is
required for Akt-mediated oncogenesis [10]; therefore, inhibition
of all components of this pathway is necessary to prevent tumor
growth. Our data indicate that, in addition to inhibition of Akt
activation, BEZ235 effectively blocks this residual signaling
through 4E-BP1, which, when combined with temsirolimus
inhibition of rS6K, synergistically blocks all arms of the PI3K/
Akt/mTOR pathway. Besides the observed inhibition of 4E-BP1
and rS6 with combined BEZ235 (dual PI3K/mTOR inhibitor)
and temsirolimus (mTORC1 inhibitor), another possibility might
explain the observed synergy. Temsirolimus and BEZ235 target
different structural domains of mTOR: temsirolimus is an
allosteric inhibitor that targets the FKBP12-rapamycin-binding
(FRB) domain while BEZ235 is a catalytic inhibitor that targets the
kinase domain. The inhibitory potential of targeting two
structurally distinct regions of the same protein may, therefore,
contribute to the synergistic effect we observed when cells were
treated with temsirolimus and BEZ235 compared to single agent
treatment alone.
It has previously been shown that treatment with BEZ235 or
ZSTK474 results in cell cycle arrest at G1 [27,37]. Our study
demonstrates that cells were more likely to arrest in G1 if they had
been treated with either BEZ235 or ZSTK474 with temsirolimus
compared to controls or single agent treatment. This may be
attributed to the ability of BEZ235 to promote increased
expression of the CDKI p27 [27]. Accordingly, we also detected
elevated p27 expression when endometrial cancer cells were
treated with BEZ235 alone or in combination with temsirolimus.
While inhibition of prosurvival Akt signaling is cytotoxic, the
mechanism of cell death involves autophagy and apoptosis [26].
We observed a decrease in the autophagy marker, LC-3I, in
response to dual mTOR/PI3K inhibition, implicating autophagy.
Others have shown that depletion of all three Akt isoforms
promoted tumor regression through initiation of autophagy [29],
and inhibition of mTOR with the alkylphospholipid perifosine
induces autophagic cell death [28]. BEZ235 has also been shown
to induce caspase-independent apoptosis in a mechanism that
includes PARP cleavage [30], which we also observed in our study.
Taken together, these data suggest that the mechanism of cell
death is through autophagy and caspase-independent apoptosis.
Molecular profiling of the endometrial cancer cell lines revealed
that sensitivity toward drug treatment correlates with loss of PTEN
expression and hyper-activation of Akt. In endometrial tumors,
loss of PTEN has previously been shown to correlate with elevated
Akt phosphorylation and results in poor outcomes [17,38]. Our
findings are consistent with earlier studies showing low expression
of PTEN in RL95-2, AN3CA, ECC-1, and Ishikawa H cells and
high expression of PTEN in Hec50, Hec1A, and KLE cells [4,39].
Furthermore, RL95-2, AN3CA, ECC-1, and Ishikawa H cells
harbor mutant PTEN, whereas KLE, Hec50, Hec1A, and Hec1B
(a substrain of Hec1A) cells express wildtype PTEN [40,41]. The
fact that Hec50 cells contain both wildtype PTEN and high Akt
phosphorylation can be explained by recent data demonstrating
that PI3KR1, a regulatory subunit of PI3K, is mutated in Hec50
cells and thus may phenocopy loss of PTEN [4]. Additional
investigation is necessary to understand why Ishikawa H cells,
which have high Akt phosphorylation and a loss of active PTEN,
are relatively resistant to temsirolimus. These data highlight the
fact that molecular profiling does not always predict for response
due to the complexity of pathways governing tumor initiation and
progression. Furthermore, basal Akt phosphorylation correlates
with response to another rapalog, RAD001, in a panel of various
cancer cell lines [8]. Studies involving PTEN
+/2 mice or cell lines
devoid of PTEN show that PTEN-deficient tumors are sensitive to
mTOR inhibition [20]. A phase I clinical trial demonstrated that
63% of patients with PTEN-negative tumors displayed tumor
regression when treated with drugs targeting the PI3K/Akt/
mTOR signaling pathway [42]. These results are consistent with
our data that cell lines with little or no PTEN are more sensitive to
temsirolimus alone and with the combination of temsirolimus and
BEZ235. In accord with our findings, single-agent BEZ235 has
been shown to inhibit proliferation of endometrial cancer cells
harboring PIK3CA and/or PTEN mutations by other investigators
[43]. These studies reported herein promote a further under-
standing of the potential underlying mechanisms of both primary
cell resistance and the development of acquired resistance after
therapy, both of which can be overcome with the combination of
mTOR and PI3K inhibitors. Our data underscore the need to
inhibit PI3K/Akt/mTOR signaling at multiple levels to achieve
sustained cellular responses. These data will enhance the rational
use of combinatorial regimens involving temsirolimus and PI3K
inhibitors in future clinical trials.
Supporting Information
Figure S1 Efficacy of temsirolimus in a panel of endometrial
cancer cell lines. The indicated cell lines were treated with vehicle
or 1 mM temsirolimus for 24 hrs. Lysates were obtained and equal
amounts Western blotted for phospho-mTOR, total mTOR,
phospho-rS6, or total r6S.
(TIF)
Figure S2 Effect of various combination therapies on Akt
phosphorylation. Ishikawa H (upper panels) or Hec50co (lower
panels) cells were treated with temsirolimus in the presence or
absence of the indicated molecular inhibitors for 24 hrs at the
noted concentrations. Lysates were obtained and equal amounts
Western blotted for phospho-Akt or total Akt.
(TIF)
Figure S3 Effect of BEZ235, ZSTK474, and temsirolimus on
rS6 phosphorylation. Phosphorylation of rS6 (P-rS6 S235/236)
was assessed after incubating cells with the indicated treatments for
24 hrs. Total rS6 expression serves as a loading control.
(TIF)
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index (CI) for combined temsirolimus and BEZ235 treatment in
the panel of eight endometrial cancer cell lines.
(TIF)
Table S2 Panel of molecular inhibitors explored for combina-
tion therapy with temsirolimus.
(TIF)
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